Free Access
Issue
Med Sci (Paris)
Volume 20, Number 4, Avril 2004
Page(s) 402 - 407
Section M/S revues
DOI https://doi.org/10.1051/medsci/2004204402
Published online 15 April 2004
  1. A consensus document of the Joint European society of cardiology/American college of cardiology committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21 : 1502–13. [Google Scholar]
  2. ISIS 2 (second international study of infarct survival) collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction : ISIS 2. Lancet 1988; 2 : 349–60. [Google Scholar]
  3. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329 : 673–82. [Google Scholar]
  4. The GUSTO IIb angioplasty substudy investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336 : 1621–8. [Google Scholar]
  5. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. On behalf of the CAPTIM study group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction : a randomised study. Lancet 2002; 360 : 825–9. [Google Scholar]
  6. Every NR, Parisons LS, Hlatky M, et al. For the myocardial infarction triage and intervention investigators. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996; 335 : 1253–60. [Google Scholar]
  7. Danchin N, Vaur L, Genès N, et al. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the « real world » : one-year results from a nation-wide French survey. Circulation 1999; 99 : 2639–44. [Google Scholar]
  8. Freemantle N, Cleland J, Young P, et al. Beta-blockade after myocardial infarction : systematic review and metaregression analysis. Br Med J 1999; 318 : 1730–7. [Google Scholar]
  9. ISIS-4 (fourth international study of infarct survival) collaborative group. ISIS-4 : a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345 : 669–85. [Google Scholar]
  10. Gruppo Italiano per lo studio della sopravvivenza nell’infarto miocardico. GISSI-3 : effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343 : 1115–22. [Google Scholar]
  11. Braunwald E. Unstable angina. A classification. Circulation 1989; 80 : 410–4. [Google Scholar]
  12. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without ST segment elevation : Results from an international trial of 9,461 patients. Circulation 2000; 101 : 2557–67. [Google Scholar]
  13. White HD, Wong CK. Risk stratification and treatment benefits in patients with non-ST-elevation acute myocardial infarction. Eur Heart J 2002; 23 : 187–91. [Google Scholar]
  14. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non ST elevation MI. A method for prognostication and therapeutic decision making. JAMA 2000; 284 : 835–42. [Google Scholar]
  15. Kaul P, Fu Y, Chang WC, et al. Prognostic value of ST segment depression in acute coronary syndromes : insights from PARAGON-A applied to GUSTO-IIb. J Am Coll Cardiol 2001; 38 : 64–71. [Google Scholar]
  16. Jernberg T, Lindahl B, Wallentin L. The combination of a continuous 12-lead ECG and troponin T. A valuable tool for risk stratification during the first 6 hours in patients with chest pain and a non-diagnostic ECG. Eur Heart J 2000; 21 : 1464–72. [Google Scholar]
  17. Heindrich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes : a meta-analysis. J Am Coll Cardiol 2001; 38 : 478–85. [Google Scholar]
  18. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345 : 1014–21. [Google Scholar]
  19. Morrow DA, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes : application of the TIMI risk score for UA/NSTEMI in PRISM-plus. Eur Heart J 2002; 23 : 223–9. [Google Scholar]
  20. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281 : 707–13. [Google Scholar]
  21. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes : a meta-analysis of all major randomised clinical trials. Lancet 2002; 359 : 189–98. [Google Scholar]
  22. The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 : 494–502. [Google Scholar]
  23. Fragmin and fast revascularisation during instability in coronary artery disease investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease : FRISC II prospective randomised multicentre study. Lancet 1999; 354 : 708–15. [Google Scholar]
  24. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344 : 1879–87. [Google Scholar]
  25. Fox KAA, Poole-Wilson PA, Henderson RA, et al. For the RITA investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction : the British heart foundation RITA 3 randomised trial. Lancet 2002; 360 : 743–51. [Google Scholar]
  26. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task force on the management of acute coronary syndromes of the European society of cardiology. Eur Heart J 2002; 23 : 1809–40. [Google Scholar]
  27. Antithrombotic trialists’ collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. Br Med J 2002; 324 : 71–86. [Google Scholar]
  28. The Scandinavian simvastatin survival study group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease : the Scandinavian simvastatin survival study (4S). Lancet 1994; 344 : 1383–9. [Google Scholar]
  29. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996; 335 : 1001–9. [Google Scholar]
  30. Heart protection study collaborative group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals : a randomised placebo-controlled trial. Lancet 2002; 360 : 7–22. [Google Scholar]
  31. The heart outcomes prevention evaluation study investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342 : 145–53. [Google Scholar]
  32. The Europa trial : design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001; 15 : 169–79. [Google Scholar]
  33. Pitt B, Waters D, Brown WV, et al. For the atorvastatin versus revascularization treatment investigators. Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341 : 70–6. [Google Scholar]
  34. Steinhubl SR, Berger PB, Mann JT, et al. For the CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 2002; 288 : 2411–20. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.